In our primary research analysis, we observed positive sentiments in the medical community towards CAR T-cell therapies. Interviewed experts state that there is now greater awareness and patient demand for Kymriah and Yescarta compared with when they launched in H2 2017. Citing reimbursement challenges as the major impediment to their current uptake, interviewed oncologists do not anticipate any sudden leap in these therapies’ market uptake. Nonetheless, they are optimistic that the increasing awareness amongst payers will soon change the current reimbursement scenario. Moreover, interviewed oncologists foresee the applicability of Kymriah and Yescarta in earlier lines of therapy. They also show great enthusiasm towards allogeneic, off-the-shelf CAR T cells.
Timeline for Administration of Kymriah Therapy for B-Cell ALL
The “so what” for decision makers: Despite the high price and potentially severe adverse events of these single-infusion, one-time therapies, there is a positive sentiment surrounding CAR T-cell therapies, not least because of their curative potential. The attractive commercial potential of these therapies is driving the high-paced development in the field and the pipeline is ripe with a plethora of candidates. CAR T-cell therapies could therefore pose a threat to currently available and emerging therapies. Both CAR T-cell therapy developers, and indeed those pharma companies not currently investing in this class, need to have their finger on the pulse of this fast moving field in order to plan and execute their R&D strategies effectively.
Key questions answered in the analysis:
- What does the typical patient journey look like for a patient receiving CAR T-cell therapy and what are the typical referral patterns?
- What are the key pricing and reimbursement issues facing Kymriah and Yescarta and what strategies are being implementing to ensure market access?
- What challenges could limit widespread adoption of autologous CD19-targeted CAR T-cell therapies? What are the future directions and opportunities?
- Who are the key players in the pipeline, and what novel targets are they exploring?
Markets covered: United States.
Methodology: Qualitative interview of 10 U.S. hematologist-oncologists and thought leaders for each of the three waves of this Special Topics Report series.
Key indications covered: Acute lymphoblastic leukemia (ALL), large B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL).
Key drugs covered: Current therapies: Kymriah, Yescarta. Emerging therapies: Lisocabtagene maraleucel, bb2121, KTE-C19, JNJ-68284528, UCART-123, CYAD-01.
Key companies mentioned: Novartis, Kite Pharma (a Gilead company), Celgene, Juno Therapeutics (a Celgene company), Bluebird Bio, Janssen Biotech, Pfizer, Cellectis, Celyad.
Discover how Kymriah and Yescarta are being adopted ins DRG’s Chimeric Antigen Receptor T-Cell Therapy Report. Learn how to access this report: